Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet Rich Plasma to Treat Idiopathic Glossopharyngeal Neuralgia (GPN)
Launched by BEIJING TIANTAN HOSPITAL · Apr 15, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment for idiopathic glossopharyngeal neuralgia (GPN), a condition that causes severe pain in the throat and ear area. The study will explore whether using pulsed radiofrequency (a type of nerve treatment) combined with platelet-rich plasma (a substance made from your own blood that can help healing) is effective and safe for relieving pain in patients who haven't found relief with medications.
To be eligible for the trial, participants need to be over 18 years old and have been diagnosed with GPN. They should also have not found relief from pain medications or have experienced side effects that they couldn’t tolerate. However, individuals with certain health issues, such as infections, serious blood or organ problems, or those who are pregnant or breastfeeding, cannot participate. If you join the trial, you can expect to receive the treatment and be followed up for at least a month to see how well it works for you. This trial is currently recruiting participants, so if you meet the criteria and are interested, you could play a role in helping improve treatment for GPN.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age \>18 years;
- • 2. diagnosed with idiopathic GPN according to the third International Classification of Headache Disorders (ICHD) classification;
- • 3. patients who failed pharmacotherapy or intolerable side effects of medication;
- • 4. undergoing PRF for GPN;
- • 5. at least 1 month of follow-up recordings.
- Exclusion Criteria:
- • 1. Patients with bilateral GPN;
- • 2. Abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiography or chest radiography;
- • 3. Infection at the puncture site;
- • 4. Previous mental illness;
- • 5. Previous history of narcotic drug abuse;
- • 6. Prior anticoagulant or antiplatelet therapy;
- • 7. An implantable pulse generator;
- • 8. Current pregnancy or breast feeding.
- • 9. Patients with incomplete medical records (lack of baseline data or postoperative follow-up data).
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported